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Long-term evidence has confirmed the involvement of an inflammatory component in
neurodegenerative disorders including Alzheimer’s disease (AD). This view is supported,
in part, by data suggesting that selected non-steroidal anti-inflammatory drugs (NSAIDs)
provide protection. Additionally, molecular players of the innate immune system
have recently been proposed to contribute to these diseases. Toll-like receptors
(TLRs) are transmembrane pattern-recognition receptors of the innate immune system
that recognize different pathogen-derived and tissue damage-related ligands. TLR4
mediated signaling has been reported to contribute to the pathogenesis of age-related
neurodegenerative diseases, including AD. Although the pathophysiology of AD is not
clear, soluble aggregates (oligomers) of the amyloid β peptide (Aβo) have been proven
to be key players in the pathology of AD. Among others, Aβo promote Ca2+ entry
and mitochondrial Ca2+ overload leading to cell death in neurons. TLR4 has recently
been found to be involved in AD but the mechanisms are unclear. Our group recently
reported that lipopolysaccharide (LPS), a TLR4 receptor agonist, increases cytosolic
Ca2+ concentration leading to apoptosis. Strikingly, this effect was only observed in
long-term cultured primary neurons considered a model of aging neurons, but not in
short-term cultured neurons resembling young neurons. These effects were significantly
prevented by pharmacological blockade of TLR4 receptor signaling. Moreover, TLR4
expression in rat hippocampal neurons increased significantly in aged neurons in vitro.
Therefore, molecular patterns associated with infection and/or brain cell damage may
activate TLR4 and Ca2+ signaling, an effect exacerbated during neuronal aging. Here,
we briefly review the data regarding the involvement of TLR4 in AD.
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TOLL LIKE RECEPTORS AND DISEASE
Toll-like receptors (TLRs) are innate immune receptors specialized in the detection of conserved
molecular patterns present in pathogens, the so-called PAMP, and self-derived molecules released
upon tissue damage, referred to as DAMP (1). The TLR family, which belongs to the type I
membrane glycoproteins, is comprised of 10 members in humans, and 12 in mice (2). TLR4 was
the first TLR identified in humans, which senses lipopolysaccharide (LPS)—a major component
of the outer membrane of Gram-negative bacteria—which exhibits potent immuno-stimulatory
activity (3). TLR4 also recognizes DAMPs released upon tissue injury, i.e., high-mobility
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group box 1 (HMGB1), heat-shock proteins, reactive oxygen
intermediates, and extracellular matrix breakdown products (4).
TLRs recognizing bacterial and fungal components (TLR 1,
2, 4, 5, 6) are expressed on the cell surface, while sensors
of viral and nucleic acids (TLR 3, 7, 8, 9, 10, 11, 12,
and 13) are localized within endosomal compartments, where
TLR4 can also be translocated (1, 2). The association of
TLRs with their specific ligands initiates intracellular signaling
routes through the adaptor MyD88, except for TLR3 that
signals via TRIF. This culminates in the induction of pro-
inflammatory molecules via NF-κB activation or antiviral
molecules via interferon regulatory factor routes (3, 5). Aberrant
TLR activation has been associated with chronic inflammation
and disease (6). A significant amount of evidence associates TLRs
to several diseases, i.e., sepsis, asthma, autoimmune diseases,
cancer, diabetes, intestinal disorders, cardiovascular diseases, and
neurodegenerative disorders (2, 6, 7).
In the nervous system, TLRs are expressed in several cell
types including neurons and glia (8), where they sense DAMPs
released by undifferentiated or necrotic/injured cells. TLR activity
has been associated with several neurodegenerative diseases,
including stroke, amyotrophic lateral sclerosis, Parkinson’s
disease, and Alzheimer’s disease (AD) (9).
TLR4 AND ALZHEIMER’S DISEASE
TLR4 is believed to mediate the neurotoxic actions of DAMPs
associated with neuronal damage involved in AD. In fact,
increasing evidence associates TLR4 with neuronal plasticity
(10, 11) and AD (12). For instance, Fujita and colleagues
have reported that HMGB1, a prototypic DAMP released
from necrotic or hyperexcitatory neurons, induces neurite
degeneration via TLR4 (13). The study showed that myristoylated
alanine-rich C-kinase substrate (MARCKS), a submembrane
protein involved in the actin network stability, is phosphorylated
at Ser46 well before aggregation of the amyloid β peptide (Aβ),
and this effect is sustained during the course of AD both in
human and mouse models of the disease. HMGB1 released
from necrotic or hyperexcitatory neurons binds to TLR4 and
activates MAP kinases, inducing MARCKS phosphorylation
leading to neurite degeneration, one of the classic hallmarks
of AD pathology. Strikingly, subcutaneous injection of an
antibody against HMGB1 prevented neurite degeneration and
reversed cognitive loss, even in the presence of Aβ plaques
(13). This study suggests a critical involvement of TLR4 in
the effects of DAMPs like HMGB1, which acts as an essential
pathogenic molecule in AD.
TLR4 is also considered to be one of the key receptors
involved in the microglial innate immune system, since it could
be involved in the production of pro-inflammatory cytokines
in AD. Consistent with this concept, gene profile analysis of
post-mortem human brains revealed an increased expression of
TLR4, TNF, and IL-6 genes in the frontal cortex of AD patients
relative to age-matched samples (14). Moreover, in the entorhinal
cortex lesioned mouse, an experimental model of hippocampal
deafferentation without amyloidosis, mimicking one of the
first neuronal losses observed in AD, tlr4 and il-1b genes
were overexpressed during the deafferentation phase but not
during the process of reinnervation. Therefore, TLR4 dependent
modulation of cytokines could be differentially regulated by
either Aβ plaques or by deafferentation processes (14).
TLR4 activation may also contribute to AD by blocking
anti-inflammatory pathways. In particular, TLR4 and TREM2
(triggering receptor expressed on myeloid cells 2, which holds
an anti-inflammatory role in the brain) may be a link between
AD and systemic inflammation, a process generally having
deleterious effects on AD progression (15). This view is supported
by data obtained from APPswe/PSEN11E9 (APP/PS1) mice, a
mouse model of cerebral amyloidosis, which showed increased
expression of both TLR4 and TREM2 in the cortex at the gene and
protein levels (15). LPS treatment further aggravated cognitive
impairment in these mice, implying that superimposition of
systemic inflammation to familial AD may accelerate AD
progression. Interestingly, after treatment of these mice with LPS,
tlr4 gene expression remained up-regulated, while trem2 gene
was down-regulated (15). These data suggest that the inhibitory
effect of TREM2 on inflammation could be downregulated by
TLR4 activation, resulting in inflammation and apoptosis in the
cortex of APP/PS1 mice without changes in the Aβ levels.
TLR4 has also recently been linked to memory loss mediated
by Aβ oligomers (Aβo) in AD. A single intracerebroventricular
injection of Aβo in C57BL/6J naïve mice substantially impaired
their recognition memory. Interestingly, it also activated
glial cells, resulting in the enhanced expression of pro-
inflammatory cytokines. Anti-inflammatory drugs prevented the
memory impairment induced by the oligomers. In addition,
cyanobacterial LPS (Cyp)—a specific TLR4 receptor antagonist—
eliminated the deleterious effects of Aβo on memory. Aβo had
no effect either on memory or glia activation in TLR4 knockout
mice, supporting the involvement of TLR4 in the noxious
effects (16). Collectively, these data suggest that Aβo may not only
act directly on synapses, but may also impact the immune system,
with TLR4 playing a major role.
A critical role of TLR4 in AD is also supported by recent
data showing that LPS, the archetypal TLR4 agonist, was detected
in brain lysates from the hippocampus and neocortex of post-
mortem AD brains (17). LPS levels in AD brains were found
to be two to three folds larger than age-matched control cases.
Strikingly, in some cases of advanced AD, there was even a 26-fold
larger level of LPS over control. The authors of the study suggest
that LPS from microbiota and/or bacterial infections in the body
may accumulate in the brain, contributing to AD. Consistently, it
has been shown that LPS is able to induce memory impairment in
rats. According to these data, Zakaria et al. have recently revised
and proposed rats injected with LPS as a novel animal model
of AD (18).
TLR4 AND CALCIUM SIGNALING IN
ALZHEIMER’S DISEASE
Strong evidence supports the involvement of intracellular
Ca2+ dyshomeostasis in aging and neurodegenerative disorders
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including AD (19). Our group, and others, have recently shown
that long-term cultures of rat hippocampal neurons display
characteristics of aged neurons (20–22). These neurons exhibit
enhanced susceptibility to neuronal cell death induced by either
neurotoxins such as the glutamate receptor agonist NMDA (20,
23) or oligomers of the amyloid β peptide 1-42 (24). These
effects are due to age-related changes in the expression of
NMDA receptors resulting in an enhanced rise in the cytosolic
Ca2+ levels induced by the neurotoxin, and in a subsequent
mitochondrial Ca2+ overload and apoptosis (23–25). These
changes have also been related to the remodeling of Ca2+
homeostasis associated with aging (26) and to the toxic effects of
Aβo at a subcellular level (22, 27). This model of in vitro neuron
aging has recently been used to investigate the effects of LPS on
apoptosis and Ca2+ signaling on hippocampal neurons.
As described above, injection of LPS in rat brains promotes
cognitive decline and brain damage and the rat injected with
LPS has been indeed proposed as an animal model of AD
(18). Interestingly, LPS induces apoptosis in rat hippocampal
neurons in primary culture depending on the time of the
culture. Specifically, short-term and long-term cultures of rat
hippocampal neurons resembling young and aged neurons,
respectively, were activated with LPS. In morphologically
identified neurons, LPS treatment promoted apoptosis only in
long-term cultures, but not in young ones, as analyzed using
fluorescence imaging of annexin V. These effects were inhibited
by the TLR4-antagonist CAY10614, indicating the involvement
of TLR4 activation (28). These effects could be mediated by TLR4
expressed in glia and/or neurons. Fluorescence imaging followed
by optical density analysis showed that identified neurons express
TLR4 and the level of expression increases in the long-term
cultured neurons. This result was further supported by double-
staining immunofluorescence proving co-expression of neuronal
specific markers and TLR4 (28). These data are consistent
with increased levels of TLR4 expression reported in the aged
human brain (10). Additionally, recent work by Hughes and
collaborators (29) suggested that in a co-culture neurons-glia, the
Aβo-driven neuronal cell death is mainly due to the Aβ-sensitized
TLR4 signaling of glial cells (astrocytes and microglia in the
co-culture) via autocrine/paracrine mechanism, thus proposing
another mechanism for Aβ toxicity via TLR4.
The effects of LPS on Ca2+ signaling have also been
investigated in cultured rat hippocampal neurons. LPS increased
cytosolic Ca2+ concentration ([Ca2+]cyt) in rat hippocampal
neurons loaded with the Ca2+ sensitive dye fura2. Consistently
with TLR4 expression, LPS increased [Ca2+]cyt only in long-
term cultures of rat hippocampal neurons but not in the short-
term cultured ones. In contrast, NMDA increased [Ca2+]cyt
both in young and aged neurons, although the effects in aged
neurons were larger (28). Again, the effects of LPS on [Ca2+]cyt
were inhibited significantly by the TLR4-antagonist CAY10614,
implying TLR4-mediated effects. Glial cells also displayed Ca2+
responses to LPS that were mostly in the form of Ca2+
oscillations in a small fraction (30%) of the glial cells (28).
On the contrary, glial cells did not display Ca2+ responses
to NMDA, as previously reported (30). The effects of LPS
on [Ca2+]cyt are not mediated by NMDARs, since low
concentrations of MK801, a NMDAR antagonist, prevented
NMDA-induced but not LPS-mediated rises in [Ca2+]cyt. In
addition, LPS treatment did not affect the expression of the
NMDAR subunits, excluding the possibility that LPS may
influence Ca2+ signaling and apoptosis by modulating expression
of NMDARs (28). These data indicate that LPS promotes
Ca2+ signaling and apoptosis in aged neurons and TLR4
contributes to these effects by NMDA receptor independent
mechanisms. However, the ion channel involved in the effects
remains unknown and additional studies are required to
address this question.
The effects of amyloid oligomers on the LPS-mediated Ca2+
signaling and apoptosis have been addressed as well. In fact,
both Ca2+ rises and apoptosis may be exacerbated in AD
by the excess of Aβo formation. This view is supported by
findings reported by Calvo-Rodriguez et al. (28) showing that co-
treatment with Aβo and the TLR4 ligand LPS, potentiates Ca2+
responses and neuronal cell death in cultures of rat hippocampal
neurons, particularly in aging. Specifically, studies performed
with long-term cultured hippocampal neurons revealed that
Aβo treatment potentiates the rise in [Ca2+]cyt induced by
LPS, suggesting a synergistic effect between TLR4 and Aβo
involving Ca2+ signaling in aged neurons. Consistently, a
48 h exposure to either LPS or Aβo fails to induce apoptosis
in young cultures. In contrast, the combination of LPS and
Aβo significantly increased the neuronal apoptosis in young
neurons, effects that were enhanced dramatically in aged neurons
(28). These data indicate that Ca2+ signals induced by TLR4
activation and Aβo may crosstalk to enhance neuronal cell
death, particularly in the aging scenario. This could be mediated
by changes in the expression of TLR4 induced by Aβo.
Supporting this, the treatment with Aβo induced changes in
TLR4 expression in neurons depending on the time in culture.
Specifically, TLR4 expression was low in young neurons and
treatment with Aβo did not influence TLR4 expression, as shown
by immunofluorescence. In contrast, after 2 weeks in vitro,
when TLR4 expression is still not significantly different from
young cultures, Aβo treatment increased significantly TLR4
expression. These effects were further exacerbated in neurons
cultured for more than 3 weeks in vitro, corresponding to
aged neurons. Therefore, evidence from this in vitro model of
neuronal aging suggests that LPS promotes Ca2+ signaling and
apoptosis in aged hippocampal neurons and that these effects
are mediated by TLR4. More importantly, TLR4 expression is
exacerbated by aging and the presence of Aβo (28) (Figure 1).
As an in vitro model, the system used in this study has
limitations: (i) as a model of aging, it might not reflect
the complexity of in vivo aging in a living brain, since
the effect and interaction with other cells in the brain and
vessels is not considered in this model; (ii) as a model of
neuroinflammation, LPS addition may be a simplistic model
of recreating it, since neuroinflammation requires many other
factors that are excluded here; (iii) as a model of AD, Aβ
oligomers are the only element taken into account in this
in vitro model, whereas the contribution of other factors
involved in AD (tau, microglial activation, astrocytic reactivity,
vessel dysfunction, etc.) remains to be explored. Nevertheless,
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FIGURE 1 | Effects of aging and amyloid oligomers on TLR4 induced Ca2+ signaling and death in rat hippocampal neurons aged in vitro. Short-term cultures of rat
hippocampal neurons, resembling young neurons, display low expression of TLR4, and the TLR4 agonist LPS has no effect on cytosolic Ca2+ concentration or cell
death. However, long-term cultured neurons resembling aged neurons display enhanced TLR4 expression, increased Ca2+ responses to LPS, and neuronal cell
death. All three of these effects are exacerbated in aged neurons treated with amyloid β oligomers involved in Alzheimer’s disease, suggesting a crosstalk between
TLR4 and amyloid β-induced Ca2+ signaling pathways.
this in vitro model is an excellent system to study certain
precise mechanisms involving Ca2+ homeostasis and/or channel
expression and helps in understanding the synergistic effects
between Aβ and LPS on aged hippocampal neurons. Further
studies in vivo animal models will be required to disentangle the
pathology underlying this disease. Consistently, recent in vivo
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data suggest the critical role of mitochondrial Ca2+ overload in
AD models (31).
Additionally, inhibiting TLR4 activation in AD may suppress
the neuroinflammatory process in the disease. The use of
chemical TLR4 antagonists as a treatment for AD might not
be of high specificity. However, a broad range of therapeutic
compounds inhibiting TLR4 have proven evidence of efficacy in
animal models of AD (32), suggesting that therapeutic blocking
of TLR4 may be a candidate therapeutic approach for AD.
CONCLUDING REMARKS
Evidence provided in this mini review suggest the critical
contribution of TLR4 in the pathogenesis of AD. TRL4 is
expressed in the brain, and its expression increases with aging
and the accumulation of amyloid β oligomers. DAMPs may also
accumulate with aging and chronic inflammation. Therefore,
the simultaneous accumulation of Aβ and DAMPs induced
TLR4 activation may occur upon stress and/or brain damage,
particularly in the context of aging. Increased serum levels of
pro-inflammatory cytokines are often associated with aging,
a chronic subclinical condition termed as inflammaging (33).
Consequently, elevation in the levels of inflammatory cytokines
induced by TLR4 activation may promote the accumulation
of Aβ, which in turn may enhance expression of TLR4 levels,
creating a damaging feedforward loop that may largely contribute
to the progression of AD (34). This loop may also be further
amplified by the age-associated increased expression of NMDA
receptors, which could be simultaneously targeted by Aβo
and perhaps by some other DAMPs. These processes may
crosstalk at the level of Ca2+ signals induced by Aβo and TLR4
independently, particularly in the aging scenario, in which this
crosstalk may contribute to brain damage during AD.
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